Member Info for Laura2022

I'm assuming they can't/wouldn't say this unless factual threeputt

As of 30 June 2024, the Company's net cash position was $8.0m (30 June 2023: $15.8m; 31 December 2023: $12.2m). We have extended our cash runway into late Q3 2025, assuming only current levels of revenue.

Also

Have a look

TRLS £1mln cap

PYC £1.3mln

Tipped

According to Telegram UK bio pharmaceutical cos have been tipped for growth in 2025

They list FAB SCLP PYC amongst others due to the labour government £1bln+ commitment to UK life science

Can't find a link sorry

Did continue

Did u vote "no" on EME TRP CPX sushi?

Is this why porky went quiet for last 3 weeks ?

London, UK - ValiRx Plc (AIM: VAL), a life science company focusing on early-stage cancer therapeutics and women's health, announces that it has conditionally raised up to £1,573,000 through a Fundraising, comprising: (i) a conditional Placing to raise £1,183,000 (before expenses), (ii) a conditional Broker Offer to be made to certain existing shareholders in the Company to raise up to £250,000 before expenses, (iii) a conditional Subscription by Directors and persons closely associated with them to raise £140,000, and (iv) conditional issue of Fundraise Warrants to all subscribers of New Ordinary Shares through, in aggregate, the allotment and issue of up to 241,999,999 New Ordinary Shares (assuming the Broker Offer is taken up in full) at the issue price of 0.65 pence  per New Ordinary Share .

This would be taken over at at least the 40-60% premium most stocks have gone for in 2024

I'm seeing a large move this week .they will constantly take 1.5mln well above bid and yet will go NT to buy often

And this Sept half year report assumes NO EXTRA revenues at all

As of 30 June 2024, the Company's net cash position was $8.0m (30 June 2023: $15.8m; 31 December 2023: $12.2m). We have extended our cash runway into late Q3 2025, assuming only current levels of revenue.

Andrey

Thanks for that

Why do you continue to invest where every single post is negative and critical?

Valuation of Absci (Nasdaq: ABSI), an albeit much-larger US/Canadian-based firm that has an AI-led approach to antibody drug design. This company has a market capitalisation of $447m and cash of $145m, hence an EV of $302m.

Precision medicine in Northern Ireland has received a £55m shot in the arm thanks to a joint effort from industry and academia.

Economy Minister Conor Murphy launched the Future Medicines Institute (FMI) at Queen’s University on Wednesday. It’s backed by £35m from the NI Executive and £20m from NI companies in diagnostics and therapeutics.

The FMI is aimed at driving innovation and production in precision medicine, with the backing of Diaceutics plc, Fusion Antibodies plc, Randox Laboratories, Almac Group, Sonrai Analytics, Exploristics and ProAxsis.

Precision medicine is a branch of healthcare which tailors treatment and drugs to the specific needs of a patient.

Mr Murphy said: “This £55m investment in the FMI is a landmark step for precision medicine in the north which will strengthen our life and health sciences sector and reinforce the region’s role in global healthcare innovation.

“FMI will foster collaboration across industry, academia, and healthcare to accelerate the development of new drugs and diagnostics, driving growth in our economy.

This project positions Physiomics at the forefront of this exciting field of drug development

Totally agree STP

I.e for 9yrs of the decade the Tories were at the healm

Youbdo realise these retail trends have been going on for a decade ??

Yes Cbeadle

Both FAB PYC

1 generating large revenues relatove to market cap FAB half year £1.2mln half year v £5mln cap , PYC £1mln half year V £1.4mln

2 Both have cash

3 forefront of AI improving drug discovery

4 good, honest BODs

5 near to profitability in 2025

6 benefitting from UK grant funding

7 tiny market caps ( £5mln and £.14mln) versus peers on AIM

From recent results iron

Cbeadle

A.I, revenue generating stocks like FAB PYC are in prime position , don't know too much about SCLP other than that it's got oncology asset/drugs

Https://www.bbc.co.uk/news/articles/cm2eeeep0npo